No insider purchase over the last 90 days. The latest, by Anonymous (PDMR), was filed 03 Mar 2026.
Mabion S.A., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to KNF. Between 24 October 2025 and 24 October 2026, 1 insider published 5 filings.
No insider sold shares on the market over the period. Instead, the filings list 1 purchase totalling €1,176, made by 1 insider. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The filings include the largest purchase, €1,176, on 3 March 2026. The buyers include 1 senior executive.
The last insider purchase was made public on 3 March 2026, 234 days ago.
Compared with its exchange (216 companies, median 4 filings), a count of 5 filings is above the norm. Since 2026, the database holds 1 purchase and no sales by insiders of the company.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. These figures are compiled from regulatory filings published by KNF. They describe what insiders did and are not a recommendation.
FY ended December 2025 · cache
5 of 5 declarations
Mabion S.A. is a Polish company focused on the development of biological drugs. It specializes in research and production of treatments for serious diseases.
Purchases our model currently ranks for the recommendations list.
All recommendations